All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

FDA Requests Class-Wide Boxed Warning for CAR T-Cell Agents Regarding Secondary T-Cell Malignancy Risk

January 25th 2024

The FDA has called to add a class-wide boxed warning for CAR T-cell therapies to alert patients of the risk of developing secondary T-cell malignancies.

Long-Term ADT Plus High-Dose Radiation Provides Survival Advantage in High-Risk Prostate Cancer

January 25th 2024

Long-term androgen deprivation therapy plus radiation therapy led to survival benefits without increased toxicity in high-risk prostate cancer.

Neoadjuvant Darolutamide/ADT Followed By Radical Prostatectomy Is Safe/Effective in Localized Prostate Cancer

January 25th 2024

Neoadjuvant darolutamide with ADT followed by radical prostatectomy is safe and effective in patients with prostate cancer.

Abiraterone Acetate/Prednisone/Apalutamide Maintains HRQOL Outcomes in Prostate Cancer

January 25th 2024

Abiraterone acetate/prednisone/apalutamide after radical prostatectomy did not lead to quality of life differences vs bicalutamide in prostate cancer.

Atezolizumab Plus Cabozantinib Improves PFS Over Novel Hormonal Therapy in mCRPC

January 25th 2024

A significant progression-free survival improvement was achieved with cabozantinib plus atezolizumab vs second-line novel hormonal therapy in mCRPC.

Olaparib Plus Abiraterone/Prednisone Displays Efficacy in mCRPC

January 25th 2024

Frontline treatment with olaparib plus abiraterone/prednisone led to a PFS benefit vs olaparib or abiraterone/prednisone alone in BRCA1/2– or ATM–altered mCRPC.

Underutilization of HRR Mutation Testing in Clinic Signals Unmet Need in mCRPC

January 25th 2024

Sub-optimal integration of HRR mutation testing into clinical practice leads to a negative impact on treatment selection and outcomes in mCRPC.

Prior EBRT Shows No Correlation With Hematologic Toxicity in Patients With mCRPC Treated With Ra-223

January 25th 2024

Patients with mCRPC who received Ra-223 were not found to be at a higher relative risk of hematological toxicity if they had received prior EBRT.

Darolutamide Plus Docetaxel/ADT Does Not Increase Hospitalization in mHSPC

January 25th 2024

Darolutamide plus docetaxel/ADT was associated with a lower rate of hospitalization compared with placebo in metastatic hormone-sensitive prostate cancer.

Florida Cancer Specialists & Research Institute Best Practices Program Improves Treatment Response and Survival for Patients with Multiple Myeloma

January 25th 2024

A program developed at Florida Cancer Specialists & Research Institute improves outcomes for patients prescribed selinexor for multiple myeloma.

Pirtobrutinib Expands MCL Armamentarium, Although Sequencing Questions Remain

January 24th 2024

William Pearse, MD, discusses how the FDA approval of pirtobrutinib for relapsed/refractory mantle cell lymphoma has advanced BTK inhibitor treatment.

Individualized Approach Best Informs Choice of Frontline Immunotherapy or Targeted Therapy Combinations Across RCC Histologies

January 24th 2024

Benjamin Garmezy, MD, discusses challenges associated with navigating the current frontline armamentarium in both clear cell and variant RCC, the impact of frontline IO doublets and IO/TKI regimens on patient outcomes, and the importance of ongoing combination studies for patients with variant RCC.

MDS Research Expands Treatment Options Across Disease Subsets

January 24th 2024

Talha Badar, MBBS, MD, discusses myelodysplastic syndrome risk stratification and the FDA approval of luspatercept for patients with this disease.

KVA12123 Showcases Early Tolerability in Advanced Solid Tumors

January 24th 2024

KVA12123 demonstrated early signals of on-target activity and tolerability at all dose levels examined to date in patients with advanced solid tumors.

Ongoing ADC Development Continues to Gain Traction in Ovarian Cancer

January 24th 2024

Sarah Crafton, MD, discusses the ongoing development of agents targeting key biomarkers in ovarian cancer, such as FRα and HER2; expands on the integration of mirvetuximab soravtansine into clinical practice and its investigation in earlier lines; and emphasizes the importance of continued patient enrollment onto ongoing or planned ADC trials in ovarian cancer.

NECTIN-4 Offers Attractive Target in Urothelial Cancer and Beyond

January 24th 2024

As the treatment paradigm in urothelial cancer expands to include agents directed at various targets, NECTIN-4 has emerged as a promising treatment target.

More Than 125 Dana-Farber Affiliated Faculty Named as 2024 Top Doctors™ in Boston Magazine

January 24th 2024

More than 125 Dana-Farber affiliated doctors have been included in Boston magazine's annual "Top Doctors" guide.

Vice President of ASH Will Focus on Gene Therapies, ASH’s Global Impact

January 24th 2024

The field of hematology is experiencing significant advancements as promising new therapies for malignancies and GVHD continue to emerge.

BTK Inhibitor–Associated AEs Can Influence Treatment Selection in MCL

January 23rd 2024

William Pearse, MD, discusses the roles of acalabrutinib and zanubrutinib in mantle cell lymphoma, as well as the adverse effect profiles of each agent.

Data From ESMO 2023 Further Define Treatment Paradigm in Advanced Melanoma

January 23rd 2024

Oncologists reviewed data from clinical trials in the field of melanoma that could add clarity to treatment standards and lead to improved patient care.